$ANIK (Anika Therapeutics Inc)

$ANIK {{ '2016-02-25T16:55:15+0000' | timeago}} • Announcement

$ANIK said that it will enter into an accelerated share repurchase (ASR) program to repurchase $25MM of its outstanding common stock. The company plans to utilize existing cash on hand to fund the ASR program. $ANIK expects the ASR program to commence in late Feb. 2016 and to be completed in 3Q16.

$ANIK {{ '2017-07-24T22:09:19+0000' | timeago}} • Announcement

$ANIK said regulatory authorities in India granted approval to MONOVISC, its single injection viscosupplement for the treatment of pain associated with osteoarthritis of all human synovial joints. $ANIK plans to expand MONOVISC into India, Australia, New Zealand and other international markets over the next 6-9 months.

$OSUR {{ '2017-07-24T18:41:34+0000' | timeago}} • Announcement

Medical devices maker $OSUR said its OraQuick HIV Self-Test has been selected by UNITAID and Population Services International for use in the phase-2 HIV Self-Testing Africa project. The Self-Testing will be conducted in countries like Malawi, Zambia, Zimbabwe and South Africa over a two-year period.

$ANIK {{ '2017-07-17T22:07:56+0000' | timeago}} • Announcement

$ANIK announced preliminary revenue for 2Q17. The company expects total revenue growth to be 23-26% YoY, including licensing, milestone and contract revenue of approx. $5MM as a result of the milestone payment associated with MONOVISC.

$ANIK {{ '2017-07-17T22:07:36+0000' | timeago}} • Announcement

$ANIK will receive a $5MM milestone payment under the terms of its license agreement with its US commercial partner. The milestone payment was triggered by MONOVISC achieving $100MM in US end-user sales within a consecutive 12-month period at the end of June 2017. The company will recognize this milestone payment as revenue in 2Q17.

$OSUR {{ '2017-06-27T12:34:45+0000' | timeago}} • Announcement

$OSUR has signed an agreement with Bill & Melinda Gates Foundation, under which the company will offer its OraQuick HIV Self-Test at an affordable price in 50 developing countries with funding from the foundation. The funding will comprise support payments tied to the volume of product sold by OraSure, and reimbursement of certain related costs.

$MMSI {{ '2017-06-22T16:08:44+0000' | timeago}} • Announcement

$MMSI received 513(f)(2) (de novo) classification from the FDA to expand indication for $MMSI's Embosphere Microspheres. The indication now includes prostatic artery embolization (PAE) for symptomatic benign prostatic hyperplasia (BPH).

$OSUR {{ '2017-06-22T12:43:35+0000' | timeago}} • Announcement

Point of care diagnostic tests and specimen collection devices manufacturer $OSUR appointed Mara Aspinall as a member of the company's BoD. Aspinall will also serve on the Audit and Compensation Committees of the Board.

$SGEN {{ '2017-06-15T12:21:22+0000' | timeago}} • Announcement

Pharma firms $SGEN and $BMY presented an interim analysis from the phase 1/2 clinical trial of  lymphoma drugs Adcetris and Opdivo in relapsed or refractory classical Hodgkin lymphoma, at the International Conference on Malignant Lymphoma in Switzerland. The drugs have not been approved, in combination, for the condition or for other indications.

$SCLN {{ '2017-06-08T13:30:40+0000' | timeago}} • Announcement

Pharma company $SCLN has entered into a definitive merger agreement with a consortium of investors under which the latter will acquire all the outstanding shares of SciClone for $11.18 per share in cash. The transaction will be funded through a combination of equity and debt financing. The deal is expected to close this calendar year.

$NUVA {{ '2017-06-01T12:44:03+0000' | timeago}} • Announcement

$NUVA appointed Skip Kiil as EVP, International. In this role, Kiil will oversee the company's international operations, reporting to NuVasive's chairman and CEO, Gregory Lucier, and serving on the company's executive leadership team.

$ANIK {{ '2017-05-31T13:54:58+0000' | timeago}} • Announcement

Biotech firm $ANIK announced its plan to present phase 3 data on Cingal, a drug for the treatment of symptoms associated with osteoarthritis, at the annual congress of the European Federation of National Associations of Orthopedics and Traumatology this year. Cingal is Anika's novel hyaluronic acid-orticostroid combination viscosupplement.

$ANIK {{ '2017-05-25T17:56:07+0000' | timeago}} • Announcement

$ANIK announced the enrollment of the first patient in its supplemental Phase 3 trial evaluating the efficacy and safety of CINGAL, its novel HA-corticosteroid combination viscosupplement for the treatment of symptoms associated with osteoarthritis (OA) of the knee.

$ANIK {{ '2017-05-22T12:55:14+0000' | timeago}} • Announcement

$ANIK announced the publication of Phase 3 data demonstrating the efficacy and safety of Cingal, its novel HA-corticosteroid combination viscosupplement for the treatment of symptoms associated with osteoarthritis of the knee.

$SGMO {{ '2017-05-11T12:04:01+0000' | timeago}} • Announcement

$SGMO said it is eligible to receive potential milestone payments of up to $475MM, including up to $300MM for the development and commercialization of SB-525 and up to $175MM for additional Hemophilia A gene therapy product candidates that may be developed under the collaboration with $PFE.

$SGMO {{ '2017-05-11T12:03:12+0000' | timeago}} • Announcement

$SGMO said it will be responsible for conducting the SB-525 Phase 1/2 clinical study and certain manufacturing activities. $PFE will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525 and additional products, if any.

$SGMO {{ '2017-05-11T12:02:25+0000' | timeago}} • Announcement

$SGMO and $PFE announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy programs for Hemophilia A, including SB-525, one of $SGMO's four lead product candidates, which $SGMO expects will enter the clinic this quarter. $SGMO will receive a $70MM upfront payment from $PFE.

$SCLN {{ '2017-05-10T20:20:09+0000' | timeago}} • Announcement

$SCLN's Zadaxin revenue for 1Q17 grew 17% to $39.5MM from 1Q16. Of these, $4.2MM was attributed to revenues from sales generated in 4Q16 but recognized in 1Q17. This is a result of 4Q sales that were above the reference tender price under provision in the agreement with its China distributor to share in burden of price reductions.

$SCLN {{ '2017-05-10T20:19:54+0000' | timeago}} • Announcement

$SCLN reported a jump in 1Q17 earnings driven by favorable impact from the additional revenue recognition for Zadaxin 4Q sales and Chinese government subsidy. Net income rose to $14.6MM or $0.28 per share from $7.9MM or $0.15 per share last year. Revenue grew 18% to $42.9MM. Non-GAAP EPS increased to $0.31 from $0.19.

$MDXG {{ '2017-04-28T18:56:53+0000' | timeago}} • Announcement

$MDXG sees 2Q17 revenue at $73.5-75MM, pushing the FY17 revenue guidance to $303.5-307MM. Gross profit margins for the year is expected to be 86-88%, with operating earnings growing by 90% or greater. MiMedx estimates GAAP EPS to be $0.18-0.20, with net earnings rising over 95% for FY17.

$MDXG {{ '2017-04-28T18:52:27+0000' | timeago}} • Announcement

$MDXG's revenue soared 36% to $72.6MM in 1Q17, as biopharma product maker's net income more than tripled to $4.3MM from last year's $1.2MM. Earnings jumped to $0.04 per diluted share from last year's $0.01 a share, helped by revenues from Wound Care segment rising 40% and SSO segment growing by 26%.

Recent Transcripts

MMSI (Merit Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
NURO (NeuroMetrix Inc.)
Thursday, July 20 2017 - 12:00pm
SRPT (Sarepta Therapeutics, Inc.)
Wednesday, July 19 2017 - 8:30pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
SCLN (SciClone Pharmaceuticals, Inc.)
Wednesday, May 10 2017 - 8:30pm
MZOR (Mazor Robotics Ltd.)
Wednesday, May 10 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
ANIK (Anika Therapeutics Inc)
Thursday, May 4 2017 - 1:00pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
OSUR (OraSure Technologies, Inc.)
Wednesday, May 3 2017 - 9:00pm
STAA (STAAR Surgical Company)
Wednesday, May 3 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 8:30pm
SHPG (Shire plc)
Tuesday, May 2 2017 - 1:00pm
MDXG (MiMedx Group, Inc.)
Friday, April 28 2017 - 2:30pm
SNMX (Senomyx Inc.)
Thursday, April 27 2017 - 9:00pm
MMSI (Merit Medical Systems, Inc.)
Thursday, April 27 2017 - 9:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
SRPT (Sarepta Therapeutics, Inc.)
Thursday, April 27 2017 - 8:30pm
NUVA (NuVasive, Inc.)
Tuesday, April 25 2017 - 8:30pm

AlphaGraphics you may like